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Background: In the last decade, adult mortality in the United States has continued its long-run decline, while
diabetes prevalence has increased. It is unknown whether the additional person-years lived in the adult
population have mostly been spent in a diseased or a disease-free state. Furthermore, although illness and
death are stochastic processes, little is known about the variance in diabetes-free life expectancy (DFLE)
when compared across ages. More generally, methods of obtaining the variance of complex life table quantities
are under-explored.
Objective: Estimate DFLE and its variance in the United States in 2000 and 2010.
Methods: Data on diabetes prevalence for ages 20+ come from the National Health and Nutrition
Examination Surveys (NHANES), 1999-2000 (n=4,205) and 2009-2010 (n=5,752). Diabetes prevalence was
defined as HbA1c at least 6.5% or taking diabetes medication. Deaths and population counts by age and sex
come from the Human Mortality Database, covering the entire U.S. population. DFLE was estimated using
Sullivan’s method. Three methods of estimating variance in DFLE were explained and compared: the delta
method, Monte Carlo simulation, and bootstrapping.
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delta method produced the smallest estimates of variance of DFLE, followed by Monte Carlo. Bootstrapping
produced variance estimates that were by far the largest, often ten times larger than the Monte Carlo variances.
Differences across methods in the variance in estimated diabetes prevalence accounted for most of the
differences across methods in the variance of DFLE.
Conclusions: The vast majority of the person-years of life gained by the U.S. adult population between 2000
and 2010 were spent with diabetes. Variance in DFLE arises mostly from variance in estimated disease
prevalence. The variance of life-table quantities can be obtained using multiple methods, and the appropriate
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Abstract 
 
Background: In the last decade, adult mortality in the United States has continued its long-run decline, 
while diabetes prevalence has increased. It is unknown whether the additional person-years lived in the 
adult population have mostly been spent in a diseased or a disease-free state. Furthermore, although 
illness and death are stochastic processes, little is known about the variance in diabetes-free life 
expectancy (DFLE) when compared across ages. More generally, methods of obtaining the variance of 
complex life table quantities are under-explored. 
 
Objective: Estimate DFLE and its variance in the United States in 2000 and 2010.  
 
Methods: Data on diabetes prevalence for ages 20+ come from the National Health and Nutrition 
Examination Surveys (NHANES), 1999-2000 (n=4,205) and 2009-2010 (n=5,752). Diabetes prevalence 
was defined as HbA1c at least 6.5% or taking diabetes medication. Deaths and population counts by age 
and sex come from the Human Mortality Database, covering the entire U.S. population. DFLE was 
estimated using Sullivan’s method. Three methods of estimating variance in DFLE were explained and 
compared: the delta method, Monte Carlo simulation, and bootstrapping. 
 
Results: Although life expectancy at age 20 rose by approximately 3 years for both males and females 
between 2000 and 2010, DFLE at age 20 did not change during this decade. At age 70, life expectancy 
rose by 2.5 years for males and 2.7 years for females, but DFLE rose only 0.7 years for males and 0.8 
years for females. For all methods, both sexes and in both years, variance in DFLE was larger at younger 
ages (males, 2000, age 20, delta method: 0.020) than at older ages (males, 2000, age 70, delta method: 
0.012). For any given age/sex/year, the delta method produced the smallest estimates of variance of 
DFLE, followed by Monte Carlo. Bootstrapping produced variance estimates that were by far the largest, 
often ten times larger than the Monte Carlo variances. Differences across methods in the variance in 
estimated diabetes prevalence accounted for most of the differences across methods in the variance of 
DFLE. 
 
Conclusions: The vast majority of the person-years of life gained by the U.S. adult population between 
2000 and 2010 were spent with diabetes. Variance in DFLE arises mostly from variance in estimated 
disease prevalence. The variance of life-table quantities can be obtained using multiple methods, and 
the appropriate method for a given research problem will vary. 
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Diabetes, Life Expectancy, Sullivan Method, National Health and Nutrition Examination Survey 
(NHANES), statistical demography 
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Introduction and Background 
 
The most basic indicator of mortality in a population is life expectancy (LE), which is calculated from a 
set of age-specific mortality rates using a single-decrement life table [1]. When using current (cross-
sectional) mortality rates, LE at birth measures the average length of time a newborn would live if he 
were subject to the current mortality risks for his entire life. For decades, population health researchers 
have been interested in methods to combine information on mortality with information on health into 
single indices to facilitate the comparison of health and mortality across populations and over time. 
Prominent among these indices is disease-free life expectancy (DFLE), also known as healthy life 
expectancy, which measures the average length of time a disease-free individual at a given age would 
live in a disease-free state, if she were subject to the current risks of mortality and disease for her 
remaining life. DFLE can refer to expected life without any disease or expected life without a particular 
disease, such as diabetes, the subject of the analysis in this paper. A fairly simple method of calculating 
DFLE was developed by Sullivan [2], in which the person-years lived at each age in the life table 
population are apportioned to diseased and disease-free states based on the age-specific prevalence of 
disease. Consistent with the basic life table, Sullivan’s method uses a synthetic cohort approach, 
meaning it subjects the population at every age to current rates of disease and death, rather than 
observing the rates experienced by actual cohorts as they age. The synthetic cohort approach thus 
facilitates comparisons of the combined mortality-health states of a population at a point in time with 
the combined mortality-health states of the population at a different point in time. 
 
Historically, demography has been more interested in measures of central tendency, such as means (of 
which LE and DFLE are examples), than in variances. Neither of the two major demography textbooks 
published in the last 15 years discusses the estimation of variances of life table parameters [1, 3]. And in 
fact, if one were to obtain information on disease presence from every member of the population, as 
well as complete records of mortality and age-specific population counts, one could calculate DFLE 
without consideration of sampling variation. However, in reality, disease prevalence in a population is 
almost always estimated from sample data in the form of queries from national health care databases 
with incomplete coverage [4] or from health surveys [5]. The variance of estimated DFLE, or some other 
measure of its uncertainty, such as a 95% confidence interval, is therefore of interest.  
 
More fundamentally, even if the investigator had data on the entire population, one might consider the 
actual events that took place (deaths and disease cases) to be random draws from underlying, 
unobserved stochastic processes of mortality and disease. In this case, even quantities in the basic life 
table, such as LE, would have variances associated with them [6].   
 
This paper will explore three methods of estimating variances of estimated DFLE. First, the delta method 
[7], so called because it involves approximating non-linear functions by taking partial derivatives and 
using Taylor Series linearization, will be employed as an analytic way to estimate the variance of non-
linear functions of data. The delta method is widely used, but in many applications, the parameters 
estimated are functions too complex to obtain analytic confidence intervals; therefore, I will explore two 
simulation-based approaches as well. Monte Carlo simulation draws input parameters, such as 
regression coefficients, from an assumed distribution, and then calculates the output parameters of 
interest (such as DFLE) for each of m independent draws of inputs from this assumed distribution. The 
Monte Carlo variance is the variance of the output parameters from the m draws [8]. Finally, 
bootstrapping takes advantage of the property that a well-designed sample survey is representative of 
the population. By resampling observations from the sample subjects, bootstrapping recreates multiple 
simulated sample surveys and calculates DFLE for each. The bootstrap variance is again the variance of 
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the output parameters across all the resamples [9]. Both simulation-based approaches use the definition 
of the variance of an estimated parameter as the variation in the parameter over multiple independent, 
identically distributed samples. 
 
Substantively, the paper compares diabetes-free life expectancy at various adult ages in the United 
States in 2000 versus 2010. As age-specific diabetes prevalence has risen [5] and adult mortality has 
declined [10], it is not obvious whether the additional years of life gained in the adult population over 
the last decade have mostly been spent in a diseased or a disease-free state. A recent paper on 
diabetes-free life expectancy in the United States for a somewhat earlier period did not report variances 
or confidence intervals [11]. 
 
Data  
 
The basic data requirements for DFLE are a set of age- and sex-specific mortality rates and a set of age-
and sex-specific disease prevalence rates. For mortality, I use sex-specific deaths and population counts 
for ages 20 to 85+, for years 1999, 2000, 2009, and 2010, from the Human Mortality Database [12], 
which organizes death data from the National Center for Health Statistics [13–16] and population counts 
from the U.S. Census. Death data are based primarily on death certificates and cover nearly 100% of 
deaths in the United States. Since each year’s data are based on the mid-year population, averaging 
adjacent years’ life tables centers the mortality schedules on January 1, 2000 and January 1, 2010.  
 
Data on age-specific diabetes prevalence for ages 20 to 85+ come from the National Health and 
Nutrition Examination Surveys (NHANES), 1999 to 2000 and 2009 to 2010. Continuous NHANES began in 
1999, for which data are released in two-year cycles, centered on January 1 of the second year of the 
release. NHANES is a complex, multi-stage probability sample of the U.S. civilian non-institutionalized 
population. Participants complete a home interview and are then examined in a mobile examination 
center, which includes sampling participants’ blood for laboratory tests. Whenever possible, NHANES 
uses consistent laboratory procedures over time to facilitate analysis of trends in population health. 
Extensive documentation of NHANES survey, examination, and laboratory procedures and 
characteristics of the NHANES study sample are reported elsewhere [17–19]. 
 
I rely on laboratory results, rather than self-reported diagnoses, because the latter fails to capture the 
considerable number of individuals in the U.S. population with undiagnosed diabetes. A 2010 study 
estimated that 3.9 million individuals above age 20 had undiagnosed diabetes, representing 19% of the 
diabetic population [20]. Furthermore, intertemporal comparisons based on self-reported diagnosis are 
complicated by the fact that criteria for diagnosing diabetes in the clinical setting have changed over 
time [21]. Laboratory results are not available for children under age 12, and past studies have focused 
only on the population age 18 and above or 20 and above [11, 20], so I will also exclude children and 
begin with age 20. NHANES top-codes individuals aged 85 and above, and at those ages, prevalence 
barely rises at all with age [22], so I will use 85+ as the terminal age. 
 
My definition of diabetes is based on HbA1C (glycated hemoglobin). This measure reflects average 
glycemia over a prolonged period and thus has more intra-subject stability than the leading alternative, 
a measure of fasting plasma glucose (FPG) [23]. Furthermore, HbA1c-based measures of diabetes are 
more strongly associated with cardiovascular disease and death than are FPG-based measures [24].  
 
Several changes in laboratory measurement of HbA1C occurred over the course of Continuous NHANES 
(detailed elsewhere [18]), but I follow the NHANES recommendation and the methods of recent studies 
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and used HbA1C data without any corrections or adjustments [5, 18]. Individuals are considered diabetic 
if they had HbA1c ≥ 6.5% (48 mmol/mol) [25]. Because diabetes medication is expected to reduce 
glycemia, the HbA1c values of medicated persons might not capture their diabetes status correctly; 
therefore, all individuals who reported taking diabetes medication are considered diabetic. 
 
Methods 
 
Deaths and population counts from adjacent years (1999-2000 and 2009-2010) are added together to 
center the life tables on January 1 of the second year of each pair of years. Then, for each sex, standard 
life table columns – death rates , death probabilities , survival probabilities (  1 
 , 
note lower-case p), cumulative survivors , person-years lived , and life expectancies – are 
calculated using standard methods [1]. One-year age intervals are used throughout, and individuals who 
die in a given interval are assumed to die, on average, halfway through that interval. 
 
Diabetes prevalence among adults increases monotonically with age, but the increase is slow at the 
oldest ages [22]. There are not enough observations in NHANES to generate a smooth, monotonically 
increasing series of single-year age- and sex-specific prevalence estimates; this is a feature of almost any 
health survey, not a limitation specific to NHANES. Therefore, I model age- and sex-specific prevalence in 
a given year (2000 or 2010) using a logistic regression: 
 Φ    1 
       . (Eq. 1) 
In Equation 1, Px (note upper-case P) is the probability of having diabetes at age x; using the model it can 
be understood as the age-specific prevalence of diabetes. Φ is the logit of Px , the linear combination of 
the predictors. 
Prevalence is then estimated as 
   1/1  exp!
"  "  "#. (Eq. 2) 
The logit of prevalence is modeled as a linear combination of an intercept, age, and sex, but the 
prevalence is a non-linear combination of these. 
 
Sullivan’s DFLE at age x is 
 $%&  ∑ ()(* 1 
 ( , (Eq. 3) 
where , is the oldest age interval, ( is person-years lived in the ith age interval, and  is the size of the 
life-table population at exact age x. 
 
Delta Method 
 
The delta method can be used to estimate variances and confidence intervals around life table-based 
estimated parameters [26]. Suppose  is fixed (it is an arbitrary starting value fixed by the investigator), 
but  and  are random variables.  is a random variable if we consider mortality to be a stochastic 
process [6], and/or if mortality is estimated from sample data [27].  is estimated from sample data 
(NHANES prevalence) and so is a random variable. Thus, DFLE is a non-linear function of random 
variables.  
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When using a period life table, as in the current study, deaths and person-years lived at a given age are 
uncorrelated with deaths and person-years at other ages [6, 28]. Furthermore, when age-specific 
prevalence is obtained from a separate cross-sectional survey, it can be considered independent of age-
specific mortality [29]. Therefore, covariances can be ignored and the delta method yields 
 -.$%&  ∑ /01234035 6 -.(  /01234075 6 -.()(* . (Eq. 4) 
The first term in Equation 4 may be thought of as the contribution of the variance in mortality to the 
variance in DFLE, while the second term may be thought of as the contribution of the variance in disease 
prevalence to the variance in DFLE. 
 
We have 
 01234078  ∑ 3595:8;8 . (Eq. 5) 
Chiang [30] showed that  is a linear function of the cumulative probability of surviving to age x, which 
is itself a product of the probabilities ( (note lower-case p here) of surviving each age group from 0 to x: 
   <=  < 
 =, (Eq. 6a) 
    > (?(* . (Eq. 6b) 
In Equation 6a, < is the length of the age interval, and  is the average proportion of the interval lived 
by people who die in the interval. These are fixed quantities chosen by the investigator, not random 
variables [1, 30]. In the present analysis, <  = 1 and  = 0.5 for every age, corresponding to the use of 
one-year age intervals and the assumption that individuals die, on average, halfway through each single-
year age interval. Then, one can rewrite Equation 3 using survival probabilities, 
 $%&  ∑ A<( ∏ CC*  <(( ∏ C?C* 
  ∏ CC* D)(* 1 
 ( ∏ C?C* . (Eq. 7) 
Recalling that , < and  are constants, Equation 4 can thus be rewritten as 
 -.$%&  ∑ /012340E5 6 -.(  /01234075 6 -.()(* . (Eq. 8) 
The result is the following formula for the delta-method variance of disease-free life expectancy (see 
[29] and [30] for the complete derivation): 
-.$%&  F G(
 1 
 (<(1 
 (  $%&(=-.(H)?(*
 F G(
 -.(H)(* . 
(Eq. 9) 
The variance of the probability of survival within each interval, -.(, equals the variance of the 
probability of death within each interval, 
 -.(  -.1 
 (  -.(  (1 
 ($( , (Eq. 10) 
with $( the observed number of deaths in the interval, based on a manipulation of the formula for the 
variance of an estimated binomial probability [30]. 
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The variance of the estimated age-specific prevalence, -., is also estimated using the delta 
method, since  is based on fitted values calculated from a non-linear function of the logistic regression 
parameter estimates (using Equation 2). Fitting the model in Equation 1 to the data, I obtain a 3 x 1 
vector of estimated coefficients, 
 IJ  K"""L. (Eq. 11) 
The variance of the age-specific prevalence will be 
 -."   GMNMIJH
O PQRP!IJ# GMNMIJH, (Eq. 12) 
where SMNMIJTis the gradient vector of , that is, a 3 x 1 vector of the partial derivatives of  with 
respect to each of the three estimated coefficients: 
 
GMNMIJH 
UV
VV
VV
VW Φ
J!1  exp!ΦJ## X ΦJ!1  exp!ΦJ## X ΦJ!1  exp!ΦJ## YZ
ZZ
ZZ
Z[
. (Eq. 13) 
 
The gradient vector is evaluated at each age and sex, with 
 ΦJ  "  "  ". (Eq. 14) 
PQRP!IJ# is the 3 X 3 variance-covariance matrix of the estimated coefficients from the information 
matrix of the logistic model fitted to the data. 
 
Despite Chiang’s conceptualization of every life table as a realization of an underlying, unobserved 
stochastic process [6, 31, 32], it is common in studies of DFLE to consider basic life table quantities to 
have zero variance if they are calculated from deaths and population counts from the entire population 
[33, 34], as is the case with the data in this paper. Nevertheless, I will use Equation 9 with a stochastic 
life table – that is, treating quantities associated with mortality, such as , as random variables, 
following Chiang – for the purpose of elucidating the method.  
 
Monte Carlo Simulation 
 
The variance of an estimator is, by definition, the average of squared deviations from the mean of the 
estimator over many independent samples. Monte Carlo simulation (MC), commonly used in studies of 
DFLE [8, 35], uses this definition to estimate the variance of DFLE by simulating many DFLE calculations, 
each obtained from a simulated age schedule of mortality and an independent draw of the estimated 
coefficients (Equation 11), and then calculating the variance of the simulated DFLE calculations. The 
motivation for using MC is that in many applications, obtaining closed-form equation for the variance of 
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an estimator of interest, as was done in Equation 9 above, is impractical or impossible, because the 
output parameter of interest is a non-differentiable function of the data. This is clearly not the case with 
Sullivan’s DFLE, making DFLE a good opportunity to compare the variance estimated by the closed-form 
equation to that obtained via MC. 
 
To generate simulated age schedules of mortality for each sex and year, I fit a Gompertz function [1, 36] 
to the observed age-specific mortality rates: 
   \ X exp . (Eq. 15) 
Each observed mortality rate contributes $ observations to the regression that fits the Gompertz 
function, where $ is the number of deaths observed in the population at age x. This repeating of 
observations is sometimes called frequency weighting and reflects the fact that each mortality rate 
arises from a large number of observations in the population. The resulting vector of estimated 
parameters, A\] ^D, and its associated variance-covariance matrix are then used as the mean and 
covariance matrix of a bivariate Normal distribution from which the elements of a new A\] ^D are drawn. 
Using the newly drawn A\] ^D, age-specific mortality rates are calculated using Equation 15, and  and  are calculated using the standard procedures [1]. The process is repeated m independent times, 
resulting in m vectors of A\] ^D and thus m schedules of  and . 
 
Separately, the disease prevalence model in Equation 1 is fitted to the data once. The resulting IJ vector 
and  PQRP!IJ# matrix are then used as the mean and covariance matrix of a trivariate Normal 
distribution from which the elements of a new IJ vector are drawn. Using the newly drawn IJ, age- and 
sex-specific fitted prevalence values are calculated using Equation 2. Then the elements of a new IJ 
vector are drawn and the process is repeated m independent times, resulting in m vectors of IJ and thus 
m age-specific prevalence schedules. 
 
This simulation process mimics the observational data, whereby disease prevalence data is obtained 
separately from mortality data, and only then are the two inputs combined. Each of the m prevalence 
schedules is paired with one of the m  columns, and DFLE is calculated using Sullivan’s formula for the 
m pairs, 
 $%&_ C  ∑ (C)(* 1 
 (CC ;  a  1,2, … , . (Eq. 16) 
The estimated DFLE in the population is the average DFLE from these m simulations, $%&ddddddddd_ . The Monte 
Carlo-based variance estimate is  
 -." $%&  1 F$%&_ C 
 $%&ddddddddd_ 
e
C* , (Eq. 17) 
with a indexing each independent draw. I will use m=1,000, a common value in the literature [8]. 
 
Bootstrapping 
 
Like MC, bootstrapping involves simulating many estimated values of DFLE and considering the variance 
of DFLE to be the average of squared deviations from the average simulated DFLE (Equation 17). 
However, the simulated DFLEs do not arise from independent draws of parameters that define regular 
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age patterns of mortality and disease, as in MC. Rather, in bootstrapping, the simulated DFLEs arise from 
independently drawn samples of data [9, 37].   
 
Bootstrapping relies on sampling theory, whereby the subjects in a sample survey, when properly 
weighted, represent the population to which the parameters pertain. For disease prevalence, the N 
subjects that were actually sampled, and their characteristics – that is, the actual NHANES data set – are 
referred to as the empirical sample. Since the empirical sample represents the population, one can draw 
a large number of new samples from the empirical sample that will on average, based on the law of 
large numbers, also represent the population. One draws N subjects, with replacement1F
1
, from the 
empirical sample, generating a simulated sample. Then one fits the model in Equation 1 to the 
simulated sample, and the fitted prevalence values are calculated using Equation 2. The process is 
repeated m times, starting by drawing N subjects afresh, with replacement, from the empirical sample. 
The result is m independent estimates of prevalence for each age.  
 
To generate simulated age schedules of mortality for each sex and year, I consider the empirical life 
table quantities for each age x: Nx, the size of the population age x, and qx, the probability of death at 
age x. For each age, I draw deaths from a binomial distribution [6] with parameters n = NX and p = qX. 
From the distribution of sampled deaths over all ages, I calculate the life table  and  in the usual way 
[1]. The process is repeated m independent times, resulting in m schedules of  and . 
 
Each of the m prevalence schedules is paired with one of the m life tables, and, using Equation 16, m 
values of DFLE are generated. The estimated DFLE in the population is the average DFLE from these m 
simulated samples, $%&ddddddddd_ . The bootstrapped variance of DFLE is that given in Equation 17. I will again 
use m=1,000 [9]. 
 
Since bootstrapping is based on the idea that the empirical sample represents the population, it is 
important that the procedure by which we generate the simulated samples mimic the sampling 
procedure in the original sample survey [38]. Due to concern for the confidentiality of subjects, NHANES 
does not publish sufficient information to reconstruct its sampling procedure fully. Instead, for each 
subject, it provides a sampling weight along with a “pseudo-stratum” and “pseudo-PSU (primary 
sampling unit)”, or cluster, which, when used together, generate variance estimates that are 
approximately equal to those obtained when internal NHANES researchers use all sampling information 
[19, 39]. Since I am using public NHANES data, I will conduct the resampling as follows [40]. First, I divide 
the empirical sample into strata using the “pseudo-stratum” indicator for each observation. Then within 
each stratum, I sample J clusters with replacement, with J equal to the number of clusters (“pseudo-
PSUs”) in each stratum in the empirical sample. (In the NHANES public data, J is almost always 2 or 3.) 
Finally, I sample n observations (persons) with replacement from within each of the J chosen clusters, 
                                                          
1
 The justification for sampling with replacement is as follows. Suppose I take a simple random sample of 100 
people from the population of the United States. The population is so big, and the sample so small, that after I 
have sampled the first of my 100 people, the probability of being chosen for the remaining individuals in the 
sample frame remains basically unchanged: it was 100/(population of the United States) and is now 99/(population 
of the United States minus 1). Now suppose I am trying to draw a subsample of 25 people from my original sample 
of 100 people. Initially, each sampled person’s probability of being in my subsample is 25/100. After I have drawn 
one person, the probability of being in my subsample for everyone else is now 24/99, which is not the same as 
25/100. Thus, in the subsampling case, a unit’s probability of being chosen depends on whether another unit was 
chosen, and the observations are not independent. To avoid this problem, we sample with replacement, so that 
after the first person is chosen, the probability of being chosen in the next draw is still 25/100 for everyone. 
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with n equal to the number of observations in the given cluster. Thus, any given bootstrapped sample 
will likely have repeat clusters and repeat observations, just as a bootstrapped sample based on an 
empirical simple random sample will have some repeat observations. The number of (non-unique) 
observations in a given bootstrapped sample will be  
 fg  F F <ChiC*
j
h* , (Eq. 18) 
with j indexing clusters, s indexing strata, and b indexing bootstrap simulations. As with analytic 
calculation of variances, the clustering of observations in PSUs will increase the bootstrapped variance 
relative to resampling every individual observation independently. 
 
A major advantage of bootstrapped variances is that they are nonparametric, meaning they do not rely 
on any assumption about the joint distribution of the elements of IJ and do not impose a functional 
form on the age schedule of mortality rates, as MC does. The advantage of MC is that if the assumed 
distributions of IJ and of the mortality rates is approximately correct, resulting variance estimates will be 
smaller than when using bootstrapping (i.e. an efficiency gain).  
 
The methods described above are conducted separately for the 2000 and 2010 data. I used R (R core 
team, Vienna, Austria) for all computations. Computer code for all analysis is available upon request.  
 
Results 
 
Results based on the delta method are shown in Table 1. Each panel shows the following quantities for 
the given sex and year at selected ages: life expectancy (column labeled “LE”), diabetes-free life 
expectancy (column labeled “DFLE”), diabetes prevalence (“Prevalence”), estimated variance of DFLE 
(“Var.DFLE”), the value of the first summation term in Equation 9 (“1
st
 term”), estimated variance in 
diabetes prevalence (“Var.Prev”), and the estimated standard error of estimated DFLE (“SE.DFLE”). A 
comparison of panels A and B reveals important changes that occurred to U.S. males during the 2000s. 
First, life expectancy at adult ages rose by approximately 2.5 to 3 years (depending on the age) over the 
course of the decade. However, diabetes-free life expectancy barely rose at all. DFLE at age 20 rose by 
about 0.02 of a year, and DFLE at age 50 rose by about 0.33 of a year. The small gain in DFLE relative to 
LE indicates that, on average, the years of life gained over the decade were mostly spent with diabetes. 
This fact is reflected in the diabetes prevalence estimates, which are higher at every age in 2010 than in 
2000. Finally, the small DFLE gains were smallest at young ages and largest at old ages, indicating that 
the increase in diabetes prevalence at the youngest ages played an especially important role in 
contributing to the smallness of the DFLE gain. 
 
Turning to the columns showing the variance of DFLE and its components, one notes that the value of 
the first term in Equation 9 is always extremely small. Because the life tables used the entire U.S. 
population, their effective “sample size” was extremely large and variances of life-table quantities were 
tiny. At every age, the vast majority of the variance in DFLE arose from variance in the estimated 
prevalence, represented by the second term in Equation 9. We also see that the variance of DFLE was 
higher in 2010 than in 2000. Variance was higher in 2010 because longer survivorship at every age in 
2010 compared to 2000 raises the value of the /35;86 factor in Equation 9, raising the value of the second 
term in the variance equation for 2010 relative to 2000. The /;5;86part of the first term is also higher in 
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2010 due to better survivorship, but the variance in survivorship probability -.( is so miniscule that 
it renders the changes in /;5;86basically meaningless. 
 
One finds similar results when comparing U.S. females in 2000 versus 2010. Although they enjoyed gains 
in life expectancy of 2 to 3.5 years over the course of the 2000s, the gains in DFLE were very small. 
Estimated DFLE at age 20 was actually lower in 2010 than 2000, though each year’s estimate is within 
one standard error of the other year’s estimate. On average, the additional years of life gained during 
the 2000s were spent almost entirely with diabetes, due to increased prevalence at all ages. As with 
men, the small increase in estimated DFLE was smallest at young ages (negative at age 20) and largest at 
old ages.  
 
Patterns of variance are also similar for females as for males. Almost all the variance in estimated DFLE 
comes from variance in estimated prevalence, since the variances associated with mortality were so 
small. Variance of DFLE was larger in 2010 than in 2000.  
 
Table 2 shows results when using Monte Carlo simulation. Differences in LE, DFLE, and estimated 
diabetes prevalence between 2000 and 2010 for men and women follow the same patterns here as 
when using the delta method. Specifically, large increases in LE occurred over the decade for both sexes, 
but DFLE barely changed, especially at younger ages, due to higher diabetes prevalence at all ages. Since 
prevalence is modeled the same way (Equation 1) in both tables, this similarity in results is also to be 
expected; however, because the estimated prevalence in Table 2 is calculated as the mean of the 
simulations, some variation could arise due to differences in sampling error between the two methods. 
And in fact we see that for a given sex/year, DFLE at the oldest ages is smaller when using the delta 
method (Table 1) than when using MC (Table 2).  
 
When one compares the variances shown in Table 2 to those in Table 1, one finds that the variance of 
DFLE tends to be higher for a given sex/year/age when using MC than when using the delta method. The 
higher variances of DFLE appear to arise primarily because the variance in life expectancy is higher when 
using MC than when using the delta method. For almost all year/sex/age combinations, the delta-
method variance from the life table (“1
st
 term”) is smaller than the MC-based variance in LE, but the 
delta method variance in prevalence is larger than the MC-based variance in prevalence. Also, whereas 
the delta method generated variances that were larger in 2010 than in 2000 for a given age/sex, MC 
generated variances that were larger in 2000 than in 2010 for a given age/sex. 
 
Table 3 shows results when using bootstrapping. Bootstrapped estimates of LE, DFLE, and diabetes 
prevalence are very similar to MC-based estimates, leading to a now-familiar result: Between 2000 and 
2010, LE increased by almost three years for both men and women, but DFLE barely increased at all, 
especially at the youngest ages. However, for any given year/sex/age combination, the bootstrapped 
variances of DFLE and of diabetes prevalence are about ten times the corresponding variances from MC. 
For example, the estimated variance in DFLE at age 20 for males in 2000 was 0.392 when using MC and 
4.677 when using bootstrapping. This large increase in the variance of DFLE when moving from MC to 
the bootstrap is reflected in the variance in prevalence, which is about ten times larger for a given 
age/sex/year in Table 3 than in Table 2. This result illustrates the efficiency disadvantage associated 
with the bootstrap. 
 
Discussion 
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This paper explored three methods for estimation of variance of diabetes-free life expectancy (DFLE): 
the delta method, Monte Carlo simulation (MC), and bootstrapping. While all three methods produced 
similar point estimates of DFLE, the patterns of estimated variance differed somewhat. The delta 
method produced the lowest variances for any given year/sex/age combination, while bootstrapping 
produced the highest variances. A comparison of MC to bootstrapping also illustrated the loss of 
efficiency associated with using a nonparametric method, though the magnitude of the efficiency loss is 
still strikingly large. The variance of estimated age-specific disease prevalence was also surprisingly small 
when using the delta method and MC, given the relatively small sample size of NHANES. 
 
A recent paper used the National Health Interview Survey (NHIS) to compare DFLE in 1980-89 to that in 
2000-2004 [11]. The authors found that over the period in question, DFLE at age 18 declined for both 
men and women, and DFLE at age 60 remained essentially unchanged. My results paint a similarly grim 
picture, with nearly all mortality improvements balanced by increases in diabetes prevalence.  
Substantively, what this paper adds is an update based on more recent trends, the use of measured data 
to avoid the problem of changes in diagnosis standards, and estimates of variance and standard errors 
associated with DFLE. Methodologically, the contribution of the paper is to illustrate how three methods 
of variance estimation work and how results using each method compare to each other, using a simple 
but commonly used application in population health research. There have been recent advances in the 
study of stochastic life table quantities; most build on one or more of the methods described here [41–
45]. 
 
The substantive results should be interpreted cautiously. Specifically, Sullivan’s DFLE is a cross-sectional 
quantity: it illustrates the mortality and health status of the U.S. adult population at two points in time 
and quantifies the extent to which growth in diabetes-prevalence has, in a sense, “cancelled out” 
declines in mortality over the last decade. It thus relates to the major question in demography and 
epidemiology about whether population-level gains in survivorship are being enjoyed in a healthy state 
or an unhealthy state [46, 47]. But as a cross-sectional measure, it does not necessarily reflect the actual 
life-course experience of any specific cohort. It is entirely possible that any given cohort of Americans is 
living more years in a healthy state than the cohorts that preceded it. 
  
13 
 
Acknowledgements: 
Special thanks to my colleagues Nikkil Sudharsanan and Arun Hendi, with whom I worked through the 
mathematics behind the paper and who provided valuable feedback. I also acknowledge the input of 
Professors Samuel H. Preston and Dylan Small of the University of Pennsylvania. An earlier version of 
this paper was submitted in partial fulfillment of the requirements for an MA degree in Statistics at the 
Wharton School, University of Pennsylvania. 
 
Funding support:  
Research was funded by Grant Number R01AG040212 from the National Institute on Aging at the 
National Institutes of Health. I declare no competing interests. 
 
  
14 
 
References 
1. Preston SH, Heuveline P, Guillot M: Demography: Measuring and Modeling Population Processes. 
Oxford: Wiley-Blackwell; 2000. 
2. Sullivan DF: A single index of mortality and morbidity. HSMHA Health Rep 1971, 86:347–54. 
3. Wachter KW: Essential Demographic Methods. Cambridge, MA: Harvard University Press; 2014. 
4. Karpati T, Cohen CJ, Leibowitz M, Hoshen M, Feldman BS, Balicer RD: Is the diabetes epidemic 
subsiding? Trends from a large population-based observational study in Israel. Popul Health Metr 
2014:1–8. 
5. Cheng YJ, Imperatore G, Geiss LS, Wang J, Saydah SH, Cowie CC, Gregg EW: Secular changes in the 
age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care 2013, 36:2690–6. 
6. Chiang C: A stochastic study of the life table and its applications: I. Probability distributions of the 
biometric functions. Biometrics 1960, 16:618–635. 
7. Hosmer DW, Lemeshow S, May S: The Delta Method. In Applied Survival Analysis: Regression 
Modeling of Time-to-Event Data. Edited by Hosmer DW, Lemeshow S, May S. John Wiley & Sons, Inc.; 
2008(X):355–358. 
8. Salomon J, Mathers C, Murray C, Ferguson B: Methods for Life Expectancy and Healthy Life Expectancy 
Uncertainty Analysis. 2001. [World Health Organization: Global Programme on Evidence for Health 
Policy] 
9. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall/CRC Press; 
1993. 
10. Murphy SL, Xu J, Kochanek KD: Deaths : Final Data for 2010. Natl Vital Stat Reports 2013, 61. 
11. Cunningham SA, Riosmena F, Wang J, Boyle JP, Rolka DB, Geiss LS: Decreases in diabetes-free life 
expectancy in the U.S. and the role of obesity. Diabetes Care 2011, 34:2225–2230. 
12. Shkolnikov V, Barbieri M, Wilmoth J: Human Mortality Database. 2014. [Www.mortality.org] 
13. Anderson RN, DeTurk PB: United States Life Tables, 1999. National Vital Statistics Reports. 
Hyattsville, MD; 2002. 
14. Arias E: United States Life Tables , 2000. National Vital Statistics Reports. Volume 51. Hyattsville, MD; 
2002. 
15. Arias E: United States Life Tables , 2009. National Vital Statistics Reports. Volume 62. Hyattsville, MD; 
2014. 
16. Arias E: United States Life Tables, 2010. National Vital Statistics Reports. Hyattsville, MD; 2014. 
15 
 
17. National Health and Nutrition Examination Survey: National Health and Nutrition Examination 
Survey : Plan and Operations , 1999 – 2010. Hyattsville, MD; 2013. 
18. Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, Cheng YJ, Rolka DB, Williams 
DE, Caspersen CJ: Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and 
Fasting Plasma Glucose: National Health and Nutrition Examination Surveys, 1999-2010. Diabetes Care 
2013, 36:2286–2293. 
19. National Health and Nutrition Examination Survey: National Health and Nutrition Examination 
Survey: Analytic Guidelines, 1999-2010. Hyattsville, MD: Centers for Disease Control and Prevention; 
2013. 
20. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, Bainbridge KE, Fradkin JE: Prevalence 
of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes 
Care 2010, 33:562–568. 
21. Stokes A, Mehta NK: Mortality and excess risk in US adults with pre-diabetes and diabetes: a 
comparison of two nationally representative cohorts, 1988-2006. Popul Heal Metr 2013, 11:7. 
22. Fishman EI, Stokes A, Preston SH: The dynamics of diabetes among birth cohorts in the U.S. 
Diabetes Care 2014, 37:1052–9. 
23. Bonora E, Tuomilehto J: The pros and cons of diagnosing diabetes with A1C. Diabetes Care 2011, 34 
Suppl 2:S184–90. 
24. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated 
hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800–811. 
25. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 
2010, 33 Suppl 1:S62–9. 
26. Preston SH, Glei D, Wilmoth J: A New Method for Estimating Smoking-Attributable Mortality in 
High-Income Countries. Int J Epidemiol 2010, 39:430–438. 
27. Keyfitz N: Sampling Variance of Demographic Characteristics. Hum Biol 1966, 38:22–41. 
28. Chiang C: Life Table and Mortality Analysis. Geneva: World Health Organization; 1979. 
29. Mathers C: Health Expectancies in Australia: 1981 and 1988. Canberra: Australian Institute of Health; 
1991. 
30. Chiang C: The Life Table and Its Applications. Malabar, FL: Robert E. Krieger Publishing Company; 
1984. 
31. Chiang C: A stochastic study of the life table and its applications: II. Sample variance of the 
observed expectation of life and other biometric functions. Hum Biol 1960, 32:221–238. 
16 
 
32. Chiang C: A stochastic study of the life table and its applications. III. The follow-up study with the 
consideration of competing risks. Biometrics 1961, 17:57–78. 
33. Abatih E, Van Oyen H, Bossuyt N, Bruckers L: Variance estimation methods for health expectancy by 
relative socio-economic status. Eur J Epidemiol 2008, 23:243–249. 
34. Loukine L, Waters C, Choi BC, Ellison J: Impact of diabetes mellitus on life expectancy and health-
adjusted life expectancy in Canada. Popul Health Metr 2012, 10:7. 
35. Mathers CD, Iburg KM, Salomon JA, Tandon A, Chatterji S, Ustün B, Murray CJL: Global patterns of 
healthy life expectancy in the year 2002. BMC Public Health 2004, 4:66. 
36. Gompertz BL: On the Nature of the Function Expressive of the Law of Human Mortality. Philos 
Trans R Soc London 1825, 115:513–583. 
37. Efron B: The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia, PA: Society for 
Industrial and Applied Mathematics; 1982. 
38. Lumley T: Complex Surveys: A Guide to Analysis Using R. Hoboken, NJ: Wiley; 2010. 
39. National Health and Nutrition Examination Survey: Survey Methods and Analytic Guidelines. 
http://www.cdc.gov/nchs/nhanes/survey_methods.htm 2014. 
40. Alho JM, Spencer B: Statistical Demography and Forecasting. New York, NY: Springer-Verlag; 2005. 
41. Schenker N, Parsons VL, Lochner K a., Wheatcroft G, Pamuk ER: Estimating standard errors for life 
expectancies based on complex survey data with mortality follow-up: A case study using the National 
Health Interview Survey Linked Mortality Files. Stat Med 2011, 30(January):1302–1311. 
42. Lynch SM, Brown JS: A New Approach to Estimating Life Tables with Covariates and Constructing 
Interval Estimates of Life Table Quantities. Sociol Methodol 2005, 35:177–225. 
43. Lynch SM, Brown JS: Obtaining Multistate Life Table Distributions for Highly Refined 
Subpopulations from Cross-Sectional Data: A Bayesian Extension of Sullivan’s Method. Demography 
2010, 47:1053–1077. 
44. Cai L, Hayward MD, Saito Y, Lubitz J, Hagedorn A, Crimmins E: Estimation of multi-state life table 
functions and their variability from complex survey data using the SPACE Program. Demogr Res 2010, 
22:129–158. 
45. Willekens FJ, Putter H: Software for multistate analysis. Demogr Res 2014, 31(August):381–420. 
46. Crimmins E, Hayward M, Hagedorn A: Change in disability-free life expectancy for Americans 70 
years old and older. Demography 2009, 46:627–646. 
47. Crimmins EM, Beltrán-Sánchez H: Mortality and Morbidity Trends : Is There Compression of 
Morbidity ? Journals Gerontol Ser B Psychol Sci Soc Sci 2010, 66B:75–86.  
17 
 
Notes for all tables: 
LE = Life expectancy; DFLE = Diabetes-free life expectancy; Prevalence = prevalence of diabetes; Var.DFLE = estimated 
variance of DFLE; 1
st
 term = first summation term in Equation 9 in text; Var.LE = estimated variance of LE; Var.Prev = 
estimated variance of diabetes prevalence; SE.DFLE = estimated standard error of DFLE = square root of estimated 
variance. Source: Author’s calculations from Human Mortality Database and National Health and Nutrition Examination 
Surveys, 1999-2000 and 2009-2010. 
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Table 1. Life expectancy and diabetes-free life expectancy at selected ages (Delta method) 
 
A) U.S. Males, Year 2000 
     Age LE DFLE Prevalence Var.DFLE 1st term Var.Prev SE.DFLE 
20 54.675 49.327 0.017 0.020 7.86E-07 0.00002 0.141 
30 45.336 39.613 0.029 0.020 4.51E-07 0.00003 0.140 
40 36.051 30.178 0.047 0.019 4.51E-07 0.00007 0.138 
50 27.235 21.210 0.077 0.018 5.44E-07 0.00016 0.135 
60 19.102 13.063 0.123 0.016 6.69E-07 0.00040 0.127 
70 12.077 6.346 0.190 0.012 3.23E-07 0.00108 0.111 
80 6.226 1.861 0.282 0.007 4.88E-08 0.00303 0.081 
85 3.455 0.623 0.337 0.004 0 0.00482 0.065 
        B) U.S. Males, Year 2010 
     Age LE DFLE Prevalence Var.DFLE 1st term Var.Prev SE.DFLE 
20 57.372 49.345 0.022 0.030 5.99E-07 0.00001 0.172 
30 48.067 39.691 0.037 0.030 4.90E-07 0.00002 0.172 
40 38.772 30.364 0.062 0.029 4.17E-07 0.00003 0.172 
50 29.887 21.547 0.103 0.029 4.59E-07 0.00006 0.171 
60 21.833 13.624 0.164 0.028 4.29E-07 0.00018 0.168 
70 14.639 7.125 0.252 0.026 3.26E-07 0.00067 0.161 
80 8.756 2.646 0.366 0.021 9.19E-08 0.00224 0.146 
85 6.576 1.320 0.430 0.019 0 0.00349 0.137 
        C) U.S. Females, Year 2000 
     Age LE DFLE Prevalence Var.DFLE 1st term Var.Prev SE.DFLE 
20 59.234 54.436 0.013 0.016 3.48E-07 0.00001 0.126 
30 49.504 44.619 0.021 0.016 2.85E-07 0.00001 0.125 
40 39.917 34.970 0.034 0.015 3.51E-07 0.00003 0.124 
50 30.653 25.627 0.056 0.015 4.75E-07 0.00006 0.123 
60 21.937 16.844 0.091 0.014 7.35E-07 0.00013 0.120 
70 14.117 9.120 0.144 0.013 4.55E-07 0.00039 0.113 
80 7.223 3.225 0.220 0.009 1.09E-07 0.00132 0.096 
85 3.975 1.257 0.267 0.007 0 0.00239 0.084 
 
       D) U.S. Females, Year 2010 
     Age LE DFLE Prevalence Var.DFLE 1st term Var.Prev SE.DFLE 
20 62.127 54.368 0.017 0.026 2.61E-07 0.00001 0.160 
30 52.416 44.610 0.029 0.026 3.07E-07 0.00002 0.160 
40 42.831 35.067 0.049 0.025 3.53E-07 0.00004 0.159 
50 33.606 25.895 0.081 0.025 4.23E-07 0.00007 0.158 
60 24.906 17.386 0.131 0.024 4.40E-07 0.00012 0.155 
70 16.960 9.970 0.205 0.023 4.72E-07 0.00027 0.151 
80 10.287 4.312 0.307 0.020 1.92E-07 0.00077 0.142 
85 7.664 2.391 0.367 0.019 0 0.00131 0.137 
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Table 2. Life expectancy and diabetes-free life expectancy at selected ages (Monte Carlo simulations) 
 
A) U.S. Males, 2000 
      Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 54.064 48.932 0.018 0.392 5.15E-06 0.00002 0.62590 
30 44.337 39.399 0.029 0.357 4.59E-06 0.00003 0.59734 
40 34.895 30.254 0.047 0.310 3.77E-06 0.00006 0.55656 
50 25.984 21.778 0.077 0.250 2.74E-06 0.00012 0.50049 
60 17.975 14.366 0.123 0.182 1.69E-06 0.00025 0.42710 
70 11.322 8.460 0.190 0.114 6.97E-07 0.00053 0.33720 
80 6.403 4.382 0.282 0.056 1.75E-07 0.00111 0.23620 
85 4.649 3.081 0.337 0.033 3.49E-06 0.00153 0.18278 
 
       B) U.S. Males, 2010 
      Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 56.933 49.122 0.022 0.176 2.25E-06 0.00001 0.4195 
30 47.246 39.672 0.037 0.173 1.95E-06 0.00001 0.4162 
40 37.848 30.643 0.062 0.168 1.54E-06 0.00002 0.4097 
50 28.963 22.311 0.102 0.157 1.07E-06 0.00004 0.3966 
60 20.921 15.047 0.164 0.137 6.12E-07 0.00009 0.3707 
70 14.151 9.273 0.252 0.105 2.15E-07 0.00025 0.3246 
80 9.182 5.396 0.366 0.067 2.88E-07 0.00062 0.2593 
85 7.679 4.370 0.431 0.052 2.45E-06 0.00087 0.2272 
 
       C) U.S. Females, 2000 
     Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 58.441 53.854 0.013 0.224 5.73E-06 0.00001 0.4734 
30 48.523 44.090 0.021 0.209 5.39E-06 0.00001 0.4572 
40 38.733 34.544 0.035 0.188 4.72E-06 0.00003 0.4330 
50 29.247 25.432 0.057 0.158 3.60E-06 0.00005 0.3977 
60 20.419 17.141 0.091 0.121 2.13E-06 0.00010 0.3477 
70 12.856 10.267 0.144 0.079 7.48E-07 0.00024 0.2819 
80 7.435 5.563 0.221 0.044 3.68E-07 0.00059 0.2094 
85 6.066 4.439 0.268 0.034 5.65E-06 0.00091 0.1831 
 
       D) U.S. Females, 2010 
     Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 61.614 54.049 0.017 0.177 1.99E-06 0.00001 0.4210 
30 51.729 44.370 0.029 0.160 1.82E-06 0.00002 0.4004 
40 41.995 34.966 0.049 0.139 1.52E-06 0.00003 0.3727 
50 32.584 26.066 0.081 0.114 1.08E-06 0.00005 0.3375 
60 23.822 18.044 0.131 0.087 5.68E-07 0.00008 0.2956 
70 16.254 11.441 0.206 0.062 1.66E-07 0.00013 0.2482 
80 10.779 6.974 0.308 0.040 3.95E-07 0.00026 0.2002 
85 9.446 5.969 0.368 0.034 2.76E-06 0.00038 0.1839 
20 
 
Table 3. Life expectancy and diabetes-free life expectancy at selected ages (Bootstrapping) 
 
A) U.S. Males, 2000 
      Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 54.675 49.332 0.020 4.677 5.21E-05 0.00030 2.1625 
30 45.335 40.162 0.030 4.340 4.48E-05 0.00047 2.0832 
40 36.051 31.157 0.047 3.863 4.02E-05 0.00077 1.9655 
50 27.235 22.748 0.075 3.266 3.36E-05 0.00135 1.8071 
60 19.102 15.205 0.120 2.507 2.59E-05 0.00271 1.5832 
70 12.077 8.982 0.189 1.613 1.30E-05 0.00624 1.2702 
80 6.227 4.241 0.286 0.664 5.01E-06 0.01402 0.8150 
85 3.455 2.271 0.343 0.234 1.36E-05 0.01959 0.4836 
 
       B) U.S. Males, 2010 
      Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 57.372 49.135 0.024 5.138 4.71E-05 0.00026 2.2667 
30 48.067 40.021 0.039 4.897 4.13E-05 0.00044 2.2129 
40 38.772 31.085 0.063 4.502 3.36E-05 0.00074 2.1219 
50 29.887 22.752 0.103 3.950 2.71E-05 0.00130 1.9875 
60 21.833 15.476 0.167 3.218 2.08E-05 0.00260 1.7940 
70 14.639 9.429 0.259 2.197 1.25E-05 0.00583 1.4822 
80 8.756 5.041 0.379 1.096 9.87E-06 0.01188 1.0470 
85 6.576 3.654 0.444 0.667 3.63E-05 0.01544 0.8169 
 
       C) U.S. Females, 2000 
     Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 59.234 54.274 0.014 4.276 3.89E-05 0.00016 2.0678 
30 49.504 44.697 0.022 4.048 3.66E-05 0.00026 2.0120 
40 39.917 35.341 0.035 3.724 3.25E-05 0.00043 1.9296 
50 30.653 26.423 0.056 3.265 2.91E-05 0.00080 1.8071 
60 21.937 18.217 0.092 2.620 2.13E-05 0.00171 1.6186 
70 14.117 11.130 0.148 1.760 9.03E-06 0.00430 1.3266 
80 7.224 5.327 0.231 0.727 3.62E-06 0.01080 0.8525 
85 3.975 2.854 0.282 0.254 8.64E-06 0.01606 0.5040 
 
       D) U.S. Females, 2010 
     Age LE DFLE Prevalence Var.DFLE Var.LE Var.Prev SE.DFLE 
20 62.127 54.230 0.018 4.9330 3.02E-05 0.00016 2.2210 
30 52.416 44.708 0.030 4.7547 2.61E-05 0.00027 2.1805 
40 42.831 35.430 0.049 4.4777 2.31E-05 0.00046 2.1161 
50 33.606 26.671 0.080 4.0655 1.94E-05 0.00082 2.0163 
60 24.906 18.683 0.131 3.4209 1.60E-05 0.00168 1.8496 
70 16.960 11.801 0.209 2.4493 9.35E-06 0.00409 1.5650 
80 10.287 6.562 0.317 1.2931 7.89E-06 0.00951 1.1372 
85 7.664 4.760 0.379 0.782 2.34E-05 0.01332 0.8844 
 
